Patents by Inventor Stephen Charles Phillips
Stephen Charles Phillips has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8591898Abstract: The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and/or a lower urinary tract symptom (LUTS) associated with interstitial cystitis and/or painful bladder syndrome and/or bladder pain syndrome.Type: GrantFiled: December 17, 2008Date of Patent: November 26, 2013Assignee: Pfizer LimitedInventors: Ian William Mills, Stephen Charles Phillips, Arnon Rosenthal, David Peter Scholfield, David Louis Shelton
-
Publication number: 20100260775Abstract: The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and/or a lower urinary tract symptom (LUTS) associated with interstitial cystitis and/or painful bladder syndrome and/or bladder pain syndrome.Type: ApplicationFiled: December 17, 2008Publication date: October 14, 2010Inventors: Ian William Mills, Stephen Charles Phillips, Arnon Rosenthal, David Peter Scholfield, David Louis Shelton
-
Publication number: 20080234280Abstract: This invention relates to the use of an MC4 receptor agonist compound for the manufacture of a medicament for the treatment of lower urinary tract dysfunction.Type: ApplicationFiled: July 20, 2006Publication date: September 25, 2008Inventors: Gordon McMurray, Stephen Charles Phillips, Simon Lempriere Westbrook
-
Patent number: 6991916Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).Type: GrantFiled: September 7, 2001Date of Patent: January 31, 2006Assignee: Pfizer Inc.Inventors: Neil Benson, Helen Frances Boyd, Leonard Gabriel Contillo, Ian Dennis Harrow, Stephen Charles Phillips, David Harlan Singleton, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman
-
Patent number: 6878529Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).Type: GrantFiled: July 13, 2001Date of Patent: April 12, 2005Assignee: Pfizer Inc.Inventors: Ian Dennis Harrow, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman, Stephen Charles Phillips
-
Patent number: 6828473Abstract: The invention provides genetically-modified non-human mammals and genetically-modified animal cells containing a functionally disrupted PDE11A gene. Also provided by the invention are methods of screening for agents that modulate PDE11A to modulate spermatogenesis, methods of treating mammals to modulate spermatogenesis, and methods of modulating cAMP and cGMP signal transduction in cells that express PDE11A.Type: GrantFiled: November 1, 2001Date of Patent: December 7, 2004Assignee: Pfizer Inc.Inventors: Martyn Frank Burslem, Ian Dennis Harrow, Jeremy Lanfear, Stephen Charles Phillips
-
Patent number: 6794192Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.Type: GrantFiled: June 28, 2001Date of Patent: September 21, 2004Assignee: Pfizer Inc.Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
-
Publication number: 20030229002Abstract: The present invention relates to the effect of PDE11A modulation on male pro-fertility, male contraception, and female sexual dysfunction (FSD), specifically female sexual arousal disorder (FSAD), female orgasmic disorder (FOD), hypoactive sexual desire disorder (HSDD) or sexual pain disorders.Type: ApplicationFiled: February 14, 2003Publication date: December 11, 2003Applicant: Pfizer Inc.Inventors: Martyn Frank Burslem, Ian Dennis Harrow, Jeremy Lanfear, Stephen Charles Phillips, Christopher Peter Wayman
-
Publication number: 20030216407Abstract: This invention relates to the use of selective cyclic guanosine 3′,5′-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of or prevention of scarring or fibrosis in tissue.Type: ApplicationFiled: January 24, 2003Publication date: November 20, 2003Applicant: Pfizer Inc.Inventors: Richard Philip Butt, Stephen Charles Phillips
-
Publication number: 20030061625Abstract: The invention provides genetically-modified non-human mammals and genetically-modified animal cells containing a functionally disrupted PDE11A gene. Also provided by the invention are methods of screening for agents that modulate PDE11A to modulate spermatogenesis, methods of treating mammals to modulate spermatogenesis, and methods of modulating cAMP and cGMP signal transduction in cells that express PDE11A.Type: ApplicationFiled: November 1, 2001Publication date: March 27, 2003Inventors: Martyn Frank Burslem, Ian Dennis Harrow, Jeremy Lanfear, Stephen Charles Phillips
-
Publication number: 20030040041Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.Type: ApplicationFiled: June 28, 2001Publication date: February 27, 2003Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
-
Publication number: 20020177689Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).Type: ApplicationFiled: September 7, 2001Publication date: November 28, 2002Inventors: Neil Benson, Helen Frances Boyd, Leonard Gabriel Contillo, Ian Dennis Harrow, Stephen Charles Phillips, David Harlan Singleton, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman
-
Publication number: 20020102707Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).Type: ApplicationFiled: July 13, 2001Publication date: August 1, 2002Inventors: Ian Dennis Harrow, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman, Stephen Charles Phillips